These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38836509)

  • 1. Epitope Mapping of an Anti-Mouse CCR8 Monoclonal Antibody C
    Kobayashi H; Suzuki H; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Aug; 43(4):101-107. PubMed ID: 38836509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C
    Suzuki H; Saito M; Asano T; Tanaka T; Kitamura K; Kudo Y; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):110-114. PubMed ID: 35377236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Anti-Mouse CC Chemokine Receptor 8 Monoclonal Antibodies for Flow Cytometry.
    Tanaka T; Nanamiya R; Takei J; Nakamura T; Yanaka M; Hosono H; Sano M; Asano T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):65-70. PubMed ID: 33900818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C
    Saito M; Tanaka T; Asano T; Nakamura T; Yanaka M; Handa S; Komatsu Y; Harigae Y; Tateyama N; Nanamiya R; Li G; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):115-119. PubMed ID: 35471052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an Anti-Mouse CCR8 Monoclonal Antibody (C
    Saito M; Suzuki H; Tanaka T; Asano T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Dec; 41(6):333-338. PubMed ID: 35483056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.
    Roider HG; Hoff S; Tseng SY; Berndt S; Trautwein M; Filarsky K; Gritzan U; Camps J; Nadler WM; Grudzinska-Goebel J; Ellinger P; Pesch T; Soon CF; Geyer M; Gluske K; Stelte-Ludwig B; Gorjánácz M
    Clin Exp Med; 2024 Jun; 24(1):122. PubMed ID: 38856863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.
    Kidani Y; Nogami W; Yasumizu Y; Kawashima A; Tanaka A; Sonoda Y; Tona Y; Nashiki K; Matsumoto R; Hagiwara M; Osaki M; Dohi K; Kanazawa T; Ueyama A; Yoshikawa M; Yoshida T; Matsumoto M; Hojo K; Shinonome S; Yoshida H; Hirata M; Haruna M; Nakamura Y; Motooka D; Okuzaki D; Sugiyama Y; Kinoshita M; Okuno T; Kato T; Hatano K; Uemura M; Imamura R; Yokoi K; Tanemura A; Shintani Y; Kimura T; Nonomura N; Wada H; Mori M; Doki Y; Ohkura N; Sakaguchi S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35140181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope Mapping of an Anti-Mouse CXCR6 Monoclonal Antibody (Cx
    Isoda Y; Tanaka T; Suzuki H; Asano T; Nakamura T; Yanaka M; Handa S; Komatsu Y; Okuno S; Takahashi N; Okada Y; Kobayashi H; Li G; Nanamiya R; Goto N; Tateyama N; Yoshikawa T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):275-278. PubMed ID: 36301196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor-infiltrating CCR8
    Chen Q; Shen M; Yan M; Han X; Mu S; Li Y; Li L; Wang Y; Li S; Li T; Wang Y; Wang W; Wei Z; Hu C; Jin A
    J Transl Med; 2024 Jul; 22(1):709. PubMed ID: 39080766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.
    Whiteside SK; Grant FM; Gyori DS; Conti AG; Imianowski CJ; Kuo P; Nasrallah R; Sadiyah F; Lira SA; Tacke F; Eil RL; Burton OT; Dooley J; Liston A; Okkenhaug K; Yang J; Roychoudhuri R
    Immunology; 2021 Aug; 163(4):512-520. PubMed ID: 33838058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.
    Guo C; Dai X; Du Y; Xiong X; Gui X
    Cancer Immunol Immunother; 2024 Aug; 73(10):210. PubMed ID: 39123089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
    Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
    Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope Mapping of an Anti-EpCAM Monoclonal Antibody (EpMab-37) Using the Alanine Scanning Method.
    Li G; Suzuki H; Tanaka T; Asano T; Yoshikawa T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2023 Feb; 42(1):41-47. PubMed ID: 36853838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope Mapping of Anti-Mouse CCR3 Monoclonal Antibodies Using Flow Cytometry.
    Tateyama N; Asano T; Suzuki H; Li G; Yoshikawa T; Tanaka T; Kaneko MK; Kato Y
    Antibodies (Basel); 2022 Dec; 11(4):. PubMed ID: 36546900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and translational pharmacology of afucosylated anti-CCR8 antibody for depletion of tumour-infiltrating regulatory T cells.
    Gampa G; Spinosa P; Getz J; Zhong Y; Halpern W; Esen E; Davies J; Chou C; Kwong M; Wang Y; Arenzana TL; Shivva V; Huseni M; Hsieh R; Schartner J; Koerber JT; Rutz S; Hosseini I
    Br J Pharmacol; 2024 Jul; 181(13):2033-2052. PubMed ID: 38486310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.
    Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M
    Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning.
    Okada Y; Suzuki H; Tanaka T; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):44-52. PubMed ID: 38507671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.